By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Brinzolamide/brimonidine, marketed as Simbrinza, is a fixed-dose combination drug used to reduce intraocular pressure (pressure inside the eye) in individuals with ocular hypertension (high intraocular pressure) or open-angle glaucoma. Brimonidine tartrate and brinzolamide are also present. It’s a type of eye drop.\
Ocular hyperaemia (red eye), allergic reactions in the eye, and dysgeusia are the most common side effects (taste disturbances).
Open-angle glaucoma (a condition in which the aqueous humour, the watery fluid inside the eyeball, cannot drain correctly) and other causes of excessive eye pressure raise the risk of retinal and optic nerve damage (the nerve that sends signals from the eye to the brain).
This can lead to severe vision loss and perhaps blindness. Brimonidine tartrate and brinzolamide, the active ingredients, help to lower intraocular pressure by decreasing the formation of aqueous humour.
Brinzolamide inhibits an enzyme called carbonic anhydrase, which creates bicarbonate, which is required for the creation of aqueous humour, whereas brimonidine tartrate inhibits another enzyme called adenylate cyclase, which is also involved in the generation of aqueous humour. Brimonidine also enhances aqueous humour drainage from the front of the eye.
The Global BRINZOLAMIDE brimonidine market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension. The main risk factor for the onset and progression of open-angle glaucoma, or for the transformation of ocular hypertension into glaucoma, which may worsen the visual field if untreated, is elevated intraocular pressure (IOP). The cornerstone of treatment for ocular hypertension and open-angle glaucoma is IOP reduction.
Guidelines from the European Glaucoma Society recommend starting treatment with a monotherapy of prostaglandin analogues (PGAs), which are efficient first-line ocular hypertensives.
However, long-term goal IOP achieving and maintenance may not be possible with monotherapy: After 2–5 years of treatment, 40%–75% of individuals need two or more drugs to reduce their IOP enough.
During the first several years of treatment, 50% of patients need to switch from their original monotherapy, with insufficient IOP-lowering accounting for 80% of these cases.
Multiple medication use or frequent dosing can reduce patient adherence to therapy and persistence, which may result in an insufficient reduction of IOP. Fixed-dose combos reduce the frequency of administration and exposure to preservatives while offering the convenience of two or more drugs in a single formulation.
Therefore, using fixed-dose combinations may enhance patient comfort, treatment adherence, and persistence. Although topical -blockers are typically included in fixed-dose combination regimens for the treatment of glaucoma, many glaucoma patients have contraindications to this medication.
The only fixed-dose combination of ophthalmic suspension without a -blocker is brinzolamide 10 mg/mL/brimonidine 2 mg/mL. Patients with open-angle glaucoma or ocular hypertension should take BBFC three times daily in the United States and twice daily in the European Union.
Patients with open-angle glaucoma or ocular hypertension who were not sufficiently treated by PGA monotherapy have shown that BBFC dosed three times daily can significantly lower IOP.
However, there is no data on a twice-daily BBFC regimen taken in addition to PGA. In this experiment, individuals with open-angle glaucoma or ocular hypertension who were not adequately controlled on a PGA were assessed for the additive IOP-lowering effects of twice-daily BBFC.
